构建铜死亡相关lncRNA模型评估头颈鳞状细胞癌预后

doi:10.6040/j.issn.1673-3770.0.2025.048

Abstract

Abstract: Objective To construct a cuproptosis-related long non-coding ribonucleotide(lncRNA)model and explore its prognostic value in patients with head and neck squamous cell carcinoma(HNSCC), and to preliminarily explore the drug sensitivity of HNSCC patients by drug sensitivity analysis. Methods Transcriptome data, tumor mutation profiles, and clinical information of HNSCC patients were downloaded from The Cancer Genome Atlas(TCGA)database. Pearson correlation analysis was used to identify lncRNAs co-expressed with cuproptosis-related gene. Univariate Cox regression and least absolute shrinkage and selection operator(LASSO)regression were used to screen the prognostic cuproptosis-related lncRNA(CRL)and establish a prognostic model. The risk score of each patient was calculated, and the median was used as the cutoff to divide the patients into low-risk and high-risk groups for survival difference analysis. Kaplan-Meier(KM)curve, receiver operating characteristic(ROC)curve, C-index, and calibration curve were used to evaluate the performance of the prognostic model. Independent prognostic risk factors were identified by univariate and multivariate Cox regression analysis. A predictive nomogram was then constructed based on the risk scores and clinical characteristics. Functional enrichment analysis and immune infiltration analysis were performed to further explore the potential molecular mechanism and biological basis of the prognostic model. Finally, the tumor mutational burden(TMB)and drug sensitivity of patients with different prognosis were analyzed. Results A total of 781 CRLs were identified, and 9 prognostic CRLs were selected and included in the prognostic model. The KM curve showed that the high-risk group was associated with poor prognosis of HNSCC(P<0.05). In the train set, the area under the ROC curves(AUCs)of the CRL prognostic model for 1-year, 3-year, and 5-year survival rates were 0.694, 0.753, and 0.643, respectively. In addition, the C-index of the model was higher than that of the clinical characteristics. Age, tumor stage, and risk score were independent prognostic risk factors(all P<0.05). Functional enrichment analysis showed that the differentially expressed genes between the low-risk and high-risk groups were mainly enriched in immune-related proteins and functions. Immune infiltration analysis showed that the expression levels of 8 immune cells and 7 immune function scores were higher in the low-risk group. KM curve showed that patients with low TMB + low risk have the best prognosis, and patients with high TMB + high risk have the worst prognosis(P<0.05). Drug sensitivity analysis showed that cisplatin, etoposide, gemcitabine, mitomycin C, sorafenib, and vinorelbine were potential drugs for the treatment of high-risk patients, while rapamycin and phenformin were potential drugs for the treatment of low-risk patients. Conclusion The prognostic prediction model of HNSCC patients based on 9 CRLs can well predict the prognosis of HNSCC patients, and evaluated the sensitivity of patients to chemotherapy drugs to provide a reference for the study of HNSCC treatment.

Key words: Cuproptosis, Long non-coding ribonucleotide, Head and neck squamous cell carcinoma, Prognostic model, Drug sensitivity

CLC Number:

R739.6

LIU Jiahui, TIAN Ruxian, LI Yumei, SONG Xicheng. Construct of a cuproptosis-related lncRNA model to predict prognosis in head and neck squamous cell carcinoma[J].Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(2): 49-64.

References

[1] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92. doi:10.1038/s41572-020-00224-3
[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi:10.3322/caac.21834
[3] Gormley M, Creaney G, Schache A, et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors[J]. Br Dent J, 2022, 233(9): 780-786. doi:10.1038/s41415-022-5166-x
[4] Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update[J]. Eur Urol, 2015, 67(5): 913-924. doi:10.1016/j.eururo.2015.01.005
[5] Jiang YC, Huo ZY, Qi XL, et al. Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes[J]. Nanomedicine, 2022, 17(5): 303-324. doi:10.2217/nnm-2021-0374
[6] Tang DL, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death[J]. Cell Res, 2022, 32(5): 417-418. doi:10.1038/s41422-022-00653-7
[7] Wang YQ, Zhang L, Zhou FF. Cuproptosis: a new form of programmed cell death[J]. Cell Mol Immunol, 2022, 19(8): 867-868. doi:10.1038/s41423-022-00866-1
[8] Kahlson MA, Dixon SJ. Copper-induced cell death[J]. Science, 2022, 375(6586): 1231-1232. doi:10.1126/science.abo3959
[9] Jiang HY, Ma B, Xu WB, et al. A novel three-lncRNA signature predicts the overall survival of HNSCC patients[J]. Ann Surg Oncol, 2021, 28(6): 3396-3406. doi:10.1245/s10434-020-09210-1
[10] Chen Y, Luo TQ, Xu SS, et al. An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma[J]. Cancer Med, 2021, 10(7): 2268-2285. doi:10.1002/cam4.3756
[11] Li QL, Wang J, Meng XY, et al. Identification of autophagy-related gene and lncRNA signatures in the prognosis of HNSCC[J]. Oral Dis, 2023, 29(1): 138-153. doi:10.1111/odi.13889
[12] Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261. doi:10.1126/science.abf0529
[13] Zhou HY, Chen LH, Lei YJ, et al. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer[J]. Curr Probl Cancer, 2021, 45(2): 100660. doi:10.1016/j.currproblcancer.2020.100660
[14] Geeleher P, Cox N, Stephanie Huang R. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels[J]. PLoS One, 2014, 9(9): e107468. doi:10.1371/journal.pone.0107468
[15] Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha(CD79a)result in a complete block in B-cell development[J]. J Clin Invest, 1999, 104(8): 1115-1121. doi:10.1172/JCI7696
[16] Tkachenko A, Kupcova K, Havranek O. B-cell receptor signaling and beyond: the role of iGα(CD79a)/iGβ(CD79b)in normal and malignant B cells[J]. Int J Mol Sci, 2023, 25(1): 10. doi:10.3390/ijms25010010
[17] Wang YY, Xu Y, Hua QQ, et al. Novel prognostic model based on immune signature for head and neck squamous cell carcinoma[J]. Biomed Res Int, 2020, 2020: 4725314. doi:10.1155/2020/4725314
[18] Chow LQM. Head and neck cancer[J]. N Engl J Med, 2020, 382(1): 60-72. doi:10.1056/nejmra1715715
[19] Gong H, Liu ZL, Yuan CH, et al. Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma[J]. Comput Biol Med, 2024, 171: 108198. doi:10.1016/j.compbiomed.2024.108198
[20] Sun Q, Qin XM, Zhao J, et al. Cuproptosis-related LncRNA signatures as a prognostic model for head and neck squamous cell carcinoma[J]. Apoptosis, 2023, 28(1/2): 247-262. doi:10.1007/s10495-022-01790-5
[21] Zheng XW, Zheng DF, Zhang CM, et al. A cuproptosis-related lncRNA signature predicts the prognosis and immune cell status in head and neck squamous cell carcinoma[J]. Front Oncol, 2023, 13: 1055717. doi:10.3389/fonc.2023.1055717
[22] 姚天赐, 高鸿, 曹伟. 头颈部鳞状细胞癌铜死亡相关非编码长链RNA预后模型及药敏分析[J]. 中国临床药理学杂志, 2023, 39(22): 3331-3335. doi:10.13699/j.cnki.1001-6821.2023.22.029 YAO Tianci, GAO Hong, CAO Wei. Cuproptosis-long non-coding RNAs prognostic marker for head and neck squamous cell carcinoma and drug sensitivity analysis[J]. The Chinese Journal of Clinical Pharmacology, 2023, 39(22): 3331-3335. doi:10.13699/j.cnki.1001-6821.2023.22.029
[23] Li YQ. Copper homeostasis: Emerging target for cancer treatment[J]. IUBMB Life, 2020, 72(9): 1900-1908. doi:10.1002/iub.2341
[24] Zhu GC, Amin N, Herberg ME, et al. Association of tumor site with the prognosis and immunogenomic landscape of human papillomavirus-related head and neck and cervical cancers[J]. JAMA Otolaryngol Head Neck Surg, 2022, 148(1): 70-79. doi:10.1001/jamaoto.2021.3228
[25] 曹琳, 周梦娇, 丁一鸣, 等. GPR68和TIL对中晚期下咽鳞癌TPF诱导化疗疗效及预后的价值[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(2): 178-184. doi:10.3760/cma.j.cn115330-20211218-00806 CAO Lin, ZHOU Mengjiao, DING Yiming, et al. Utility of GPR68 and TIL in TPF-induced chemotherapy and prognosis evaluation in middle-advanced hypopharyngeal squamous cell carcinoma[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(2): 178-184. doi:10.3760/cma.j.cn115330-20211218-00806
[26] Shao F, Yang XY, Wang W, et al. Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis[J]. Cancer Commun, 2019, 39(1): 54. doi:10.1186/s40880-019-0401-9
[27] Bu WC, Cao MG, Wu XR, et al. Prognosis prediction of head and neck squamous cell carcinoma through the basement membrane-related lncRNA risk model[J]. Front Mol Biosci, 2024, 11: 1421335. doi:10.3389/fmolb.2024.1421335
[28] Ren JY, Yan BR, Wang XR, et al. A pyroptosis-related lncRNA risk model for the prediction of prognosis and immunotherapy response in head and neck squamous cell carcinoma[J]. Front Oncol, 2024, 14: 1478895. doi:10.3389/fonc.2024.1478895
[29] Chen Q, Shi X, Bao YY, et al. Deciphering disulfidptosis-linked lncRNA patterns as potential HNSCC biomarkers[J]. Oral Dis, 2025. doi:10.1111/odi.15283
[30] Kong JL, Sun WJ, Zhu WY, et al. Long noncoding RNA LINC01133 inhibits oral squamous cell carcinoma metastasis through a feedback regulation loop with GDF15[J]. J Surg Oncol, 2018, 118(8): 1326-1334. doi:10.1002/jso.25278
[31] Dreishpoon MB, Bick NR, Petrova B, et al. FDX1 regulates cellular protein lipoylation through direct binding to LIAS[J]. J Biol Chem, 2023, 299(9): 105046. doi:10.1016/j.jbc.2023.105046
[32] Han BA, Li S, Huang S, et al. Cuproptosis-related lncRNA SNHG16 as a biomarker for the diagnosis and prognosis of head and neck squamous cell carcinoma[J]. PeerJ, 2023, 11: e16197. doi:10.7717/peerj.16197
[33] Guo DF, Fan LW, Zeng HH, et al. Establishment and validation of a cuproptosis-related lncRNA signature that predicts prognosis and potential targeted therapy in hepatocellular carcinoma[J]. Biotechnol Genet Eng Rev, 2024, 40(2): 739-764. doi:10.1080/02648725.2023.2190640
[34] Zhang MZ, Xiao ZT, Xie YJ, et al. A cuproptosis-related lncRNA signature-based prognostic model featuring on metastasis and drug selection strategy for patients with lung adenocarcinoma[J]. Front Pharmacol, 2023, 14: 1236655. doi:10.3389/fphar.2023.1236655
[35] Liang S, Ji LT, Yu ZY, et al. Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma[J]. Hereditas, 2024, 161(1): 10. doi:10.1186/s41065-024-00311-5
[36] Zhou LQ, Cheng Q, Hu Y, et al. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation[J]. Front Oncol, 2022, 12: 1030802. doi:10.3389/fonc.2022.1030802
[37] Liu XJ, Cheng WW, Li HQ, et al. Identification and validation of cuproptosis-related LncRNA signatures as a novel prognostic model for head and neck squamous cell cancer[J]. Cancer Cell Int, 2022, 22(1): 345. doi:10.1186/s12935-022-02762-0
[38] Yang LQ, Yu JL, Tao L, et al. Cuproptosis-related lncRNAs are biomarkers of prognosis and immune microenvironment in head and neck squamous cell carcinoma[J]. Front Genet, 2022, 13: 947551. doi:10.3389/fgene.2022.947551
[39] Li YJ, Li HY, Zhang Q, et al. The prognostic value and immune landscape of a cuproptosis-related lncRNA signature in head and neck squamous cell carcinoma[J]. Front Genet, 2022, 13: 942785. doi:10.3389/fgene.2022.942785
[40] Zhao Z, Li YL, Wu YQ, et al. Deep learning-based model for predicting progression in patients with head and neck squamous cell carcinoma[J]. Cancer Biomark, 2020, 27(1): 19-28. doi:10.3233/CBM-190380
[41] Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances[J]. Nat Rev Cancer, 2018, 18(3): 148-167. doi:10.1038/nrc.2017.121
[42] Schreibelt G, Bol KF, Aarntzen EH, et al. Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy[J]. Oncoimmunology, 2013, 2(6): e24440. doi:10.4161/onci.24440
[43] Cho Y, Miyamoto M, Kato K, et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma[J]. Cancer Res, 2003, 63(7): 1555-1559.
[44] Kim SS, Shen S, Miyauchi S, et al. B cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade[J]. Clin Cancer Res, 2020, 26(13): 3345-3359. doi:10.1158/1078-0432.CCR-19-3211
[45] Attramadal CG, Kumar S, Gao J, et al. Low mast cell density predicts poor prognosis in oral squamous cell carcinoma and reduces survival in head and neck squamous cell carcinoma[J]. Anticancer Res, 2016, 36(10): 5499-5506. doi:10.21873/anticanres.11131
[46] Rodrigo JP, Sánchez-Canteli M, López F, et al. Tumor-infiltrating lymphocytes in the tumor microenvironment of laryngeal squamous cell carcinoma: systematic review and meta-analysis[J]. Biomedicines, 2021, 9(5): 486. doi:10.3390/biomedicines9050486
[47] Farah CS. Molecular landscape of head and neck cancer and implications for therapy[J]. Ann Transl Med, 2021, 9(10): 915. doi:10.21037/atm-20-6264
[48] Nathan CA, Khandelwal AR, Wolf GT, et al. TP53 mutations in head and neck cancer[J]. Mol Carcinog, 2022, 61(4): 385-391. doi:10.1002/mc.23385
[49] Chen ZG, Saba NF, Teng Y. The diverse functions of FAT1 in cancer progression: good, bad, or ugly?[J]. J Exp Clin Cancer Res, 2022, 41(1): 248. doi:10.1186/s13046-022-02461-8
[50] Cao HT, Lan TJ, Kuang SJ, et al. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer[J]. Drug Resist Updat, 2024, 76: 101095. doi:10.1016/j.drup.2024.101095
[51] Kitamura N, Sento S, Yoshizawa Y, et al. Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma[J]. Int J Mol Sci, 2020, 22(1): 240. doi:10.3390/ijms22010240
[52] Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma(GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2021, 22(4): 463-475. doi:10.1016/S1470-2045(20)30755-5
[53] Tao YG, Bardet E, Rosine D, et al. Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma-GORTEC 2004-02[J]. Radiat Oncol, 2013, 8: 40. doi:10.1186/1748-717X-8-40
[54] Vanderveken OM, Szturz P, Specenier P, et al. Gemcitabine-based chemoradiation in the treatment of locally advanced head and neck cancer: systematic review of literature and meta-analysis[J]. Oncologist, 2016, 21(1): 59-71. doi:10.1634/theoncologist.2015-0246
[55] Haffty BG, Son YH, Sasaki CT, et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials[J]. Int J Radiat Oncol Biol Phys, 1993, 27(2): 241-250. doi:10.1016/0360-3016(93)90234-m
[56] Affolter A, Samosny G, Heimes AS, et al. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines[J]. Head Neck, 2017, 39(4): 623-632. doi:10.1002/hed.24557
[57] Erjala K, Pulkkinen J, Kulmala J, et al. Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro[J]. Acta Oncol, 2004, 43(2): 169-174. doi:10.1080/02841860310023110
[58] Ren GX, Hu JZ, Wang RX, et al. Rapamycin inhibits Toll-like receptor 4-induced pro-oncogenic function in head and neck squamous cell carcinoma[J]. Oncol Rep, 2014, 31(6): 2804-2810. doi:10.3892/or.2014.3134
[59] Shen YQ, Guerra-Librero A, Fernandez-Gil BI, et al. Combination of melatonin and rapamycin for head and neck cancer therapy: suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation[J]. J Pineal Res, 2018, 64(3). doi:10.1111/jpi.12461.doi:10.1111/jpi.12461
[60] Day TA, Shirai K, O'Brien PE, et al. Inhibition of mTOR signaling and clinical activity of rapamycin in head and neck cancer in a window of opportunity trial[J]. Clin Cancer Res, 2019, 25(4): 1156-1164. doi:10.1158/1078-0432.CCR-18-2024
[61] Seo YS, Kim TH, Lim H, et al. Phenformin induces caspase-dependent apoptosis of FaDu head and neck squamous cell carcinoma cells[J]. Anticancer Res, 2019, 39(7): 3499-3506. doi:10.21873/anticanres.13496
[62] Zhuang DX, Wang SS, Deng HT, et al. Phenformin activates ER stress to promote autophagic cell death via NIBAN1 and DDIT4 in oral squamous cell carcinoma independent of AMPK[J]. Int J Oral Sci, 2024, 16(1): 35. doi:10.1038/s41368-024-00297-w

Related Articles 15

[1]	PAN Linlin, WAN Jiaming, LI Yue, HE Long. Autophagy-related long noncoding RNA is a prognostic indicator for head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 97-107.
[2]	YANG Ming, LIU Xuexia, ZHANG Hua. Progress of m6A recognition protein IGF2BPs in head and neck cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 153-161.
[3]	XIE Yulin, LEI Dapeng. Advances in the pathological study of artificial intelligence in the lymph node metastasis of head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(3): 124-129.
[4]	SONG Fei, SONG Hao, LI Yumei, MOU Yakui, SONG Xicheng. Immunomodulatory roles of tumor-derived exosomes in the microenvironment of head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(1): 92-100.
[5]	ZHANG Yonghong, ZHANG Hui, WANG Caihua, YANG Xinxin, WU Yungang, ZHAO Yufeng, PANG Taizhong, LI Xiaoyu. Construction of an immune-associated gene prognostic model and screening of targeted molecular drugs for laryngeal squamous cell carcinoma based on the TCGA database [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 54-62.
[6]	ZHOU Yijing, ZOU Jianyin, YI Hongliang, WU Hongmin. Expression of TGFBI in head and neck squamous cell carcinoma and its clinical significance [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 85-95.
[7]	YANG Yingling, GOU Haocheng, FENG Jun. Review of pyroptosis molecular mechanism and applications in head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 160-165.
[8]	SUO Anqi, YANG Xinxin. Research progress on the relationship between mitochondrial autophagy and squamous cell carcinoma of the head and neck [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 111-117.
[9]	AI Ziqin, LI Junzheng. Advances in immune vaccines for head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(2): 143-150.
[10]	ZHANG Xiaoxue, WANG Wei, LIU Jie, XU Zhenju, QIAN Yongheng, HAN Min. The bacteriological characteristics and drug sensitivity of the oropharyngeal region in children and adults with OSAHS [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(1): 35-40.
[11]	WEI Ya'nan,CHEN Xi. Progress in chemotherapy and targeted drug therapy for locally advanced head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 118-124.
[12]	ObjectiveThe aim of this study was to provide new perspectives and targets for the treatment of HNSCC by screening differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma(HNSCC)using bioinformatics. MethodsThe chip dataset, GSE109756, was downloaded from the GEO database, and the online analysis tool, GEO2R, was used to screen differentially expressed genes in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The DAVID 6.8 and STRING online software were used to analyze the function of the differentially expressed genes, their pathway enrichment, and their protein interactions. Cytoscape was used to visualize and analyze the protein interactions. The online analysis tool, X2K, was used to find the transcription factors, the kinases of differentially expressed genes, and their mutual regulatory relationship with the targeted genes. ResultsNinety-one differentially expressed genes, including 50 up-regulated and 41 down-regulated genes(P<0.05; \| logFC \| > 1), were found in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The GO and KEGG pathway analyses suggested that these differentially expressed genes were mainly enriched with immunomodulation, extracellular matrix, and other processes. Through the construction of a protein-protein interaction network, we screened CD163, VSIG4, and 3 other core differentially expressed genes(P<0.05), which were up-regulated after cetuximab treatment. In addition, our analysis shows that transcription factors, including SUZ12, TP63, and ESR1, played a key role in cetuximab treatment(P<0.05)and MAPK14, CDK1, and MAPK1 were the most important kinases during the process(P<0.05). ConclusionCD163, VSIG4, and the aforementioned transcription factors and protein kinases may be involved in the biological processes that underlie cetuximab treatment of HNSCC. This study provides new perspectives to facilitate further understanding of the biological mechanism that underlies cetuximab treatment of HNSCC and the exploration of the effectiveness of HNSCC treatment.. Analysis of differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma using bioinformaticsYU Kena¹, SUN Kaiyue², ZHANG Jie¹, JIN Peng¹ 1. Department of Otorhinolaryngology & Head and Neck Surgery, The Second Hospital of Shandong University, Jinan 250033, Shandong, China; 2. Shandong Provincial Otorhinolaryngology Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, Shandong, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 117-124.
[13]	WU Jing, LIU Yehai. Targeted therapy for head and neck squamous cell carcinoma [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 97-102.
[14]	ZHAO Jincheng, SHI Ying, ZHANG Ying, JIA Zhanhong, MA Xin, ZHANG Jingqiu, WU Zaijun, WANG Yu. Expression and methylation patterns of CDH13 in human head and neck squamous carcinoma cells. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 60-63.
[15]	LI Shenling, ZHANG Xiaotian, JIANG Xiaodan, HUANG Tianqiao, GUO Ge, LIANG Dapeng. Pathogenic bacteria and drug sensitivity in 53 patients with chronic suppurative otitis media [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(3): 31-34.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	YANG Changliang,HUANG Zhiwu,YAO Hangqi,ZHU Yong,SNU Yi . Study on auditory brainstem response[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 9 -13 .
[2]	WANG Hong-xia,WANG Peng-cheng . Expression of NSE,S100 and GFAP in retinoblastoma and its clinical significance[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 263 -264 .
[3]	YU Zhi-liang,WANG Wei-wei,WANG Ming-hua . Excision of huge epiglottis cysts under MedtrnicXPS3000 in 23 cases[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 278 -279 .
[4]	ZHANG Jian-li,WANG Yue-jian,CHEN Wei-xiong,HU Wei-wei,LI Guang-min . Immunohistochemistry and serial section in detection of lymph node micrometastasis of head and neck squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(4): 299 -303 .
[5]	. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(4): 331 -332 .
[6]	LIU Feng-an,CHEN Hong-jie,HU Hong-yi,ZHENG Shi-xin . Effect of cochlear implantation on hearing and speech rehabilitation [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(4): 333 -335 .
[7]	. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(4): 349 -349 .
[8]	CHEN Feng-hua,MA Jian-min,WANG Ning-li,WANG Jin-jin . Culture of the human Tenon′s capsule fibroblast cells in vitro[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(4): 350 -352 .
[9]	HE Shou-huan,CHEN Bin,YIN Shan-kai,SU Kai-ming,JIANG Xiao . Morphological changes of the upper airway in OSAHS patients with UPPP [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(5): 385 -388 .
[10]	ZHU Chun-sheng,CHEN Jian-qiu . Apoptotic effect of human maligant melanoma cell line A375 induced by tumor-specific recombinant TRAIL gene[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(5): 408 -411 .

Construct of a cuproptosis-related lncRNA model to predict prognosis in head and neck squamous cell carcinoma

PDF (PC)